Home » Stocks » Stoke Therapeutics

Stoke Therapeutics, Inc. (STOK)

Stock Price: $39.64 USD -0.53 (-1.32%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed
After-hours: $39.75 +0.11 (0.28%) Oct 26, 4:57 PM

Stock Price Chart

Key Info

Market Cap 1.32B
Revenue (ttm) n/a
Net Income (ttm) -42.76M
Shares Out 33.24M
EPS (ttm) -2.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $39.64
Previous Close $40.17
Change ($) -0.53
Change (%) -1.32%
Day's Open 39.39
Day's Range 36.97 - 40.78
Day's Volume 65,116
52-Week Range 15.82 - 41.00

More Stats

Market Cap 1.32B
Enterprise Value 1.12B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 33.24M
Float 15.80M
EPS (basic) -1.08
EPS (diluted) -2.66
FCF / Share -1.23
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.84M
Short Ratio 26.37
Short % of Float 18.00%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.34
Revenue n/a
Operating Income -45.66M
Net Income -42.76M
Free Cash Flow -40.51M
Net Cash 202.14M
Net Cash / Share 6.08
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -12.50%
ROE -19.22%
ROIC -1,944.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 8
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(4.69% upside)
Current: $39.64
Target: 41.50
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-35.68-12.78-5.55
Net Income-32.33-12.52-5.56
Shares Outstanding17.970.710.67
Earnings Per Share-1.80-17.65-8.29
Operating Cash Flow-31.06-10.96-5.56
Capital Expenditures-1.63-0.93-0.11
Free Cash Flow-32.69-11.89-5.67
Cash & Equivalents2231061.85
Net Cash / Debt2231061.85
Book Value224105-1.29
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Stoke Therapeutics, Inc.
Country United States
Employees 56
CEO Edward M. Kaye

Stock Information

Ticker Symbol STOK
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: STOK
IPO Date June 19, 2019


Stoke Therapeutics, an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.